How A 2001 changes current law

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

This bill amends 1 section(s) of the New Jersey statutes: N.J.S.A. 45:14-49.

• N.J.S.A. 45:14-49

  this act this act → P.L.2003, c.280 (C.45:14-40 et seq.) P.L.2003, c.280 (C.45:14-40 et seq.) d. The provisions of P.L.2003, c.280 (C.45:14-40 et seq.) shall not apply to a drug manufacturer or wholesale drug distributor, to the extent the manufacturer or wholesale drug distributor is engaged in the distribution of dialysate drugs or devices necessary to perform home dialysis on patients with end-stage renal disease, provided the following criteria are met: (1) the dialysate drugs or devices are approved by the United States Food and Drug Administration, as required by federal law; (2) the dialysate drugs or devices lawfully are held by a manufacturer or a manufacturer's agent that is properly registered as a manufacturer or wholesale drug distributor; (3) the dialysate drugs or devices are held and delivered in original, sealed labeled packaging from the manufacturing facility; (4) the dialysate drugs or devices are delivered only by the manufacturer or the manufacturer's agent and only upon receipt of a physician's order; (5) the manufacturer or manufacturer's agent delivers the dialysate drugs or devices directly to: (a) a patient with end-stage renal disease, or the patient's designee, for the patient's self-administration of dialysis therapy; or (b) a health care provider or institution for administration or delivery of the dialysis therapy to a patient with end-stage renal disease; and (6) the manufacturer shall contract with a consultant pharmacist that is properly registered by the board who will provide quality assurance assessments of home dialysis drug storage and distribution on a weekly basis.

  amended